Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Ovarian Neoplasms 6Uterine Cervical Neoplasms 3Fallopian Tube Neoplasms 3Uterine Neoplasms 2Vaginal Neoplasms 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Thyroid Neoplasms 1Stomach Neoplasms 1Small Cell Lung Carcinoma 1Rectal Neoplasms 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian, Fallopian Tube, Peritoneal Cancer, P53 Mutation 1Neoplasms 1Multiple Myeloma 1Melanoma 1Lymphoma 1Lung Neoplasms 1Hematologic Neoplasms 1Glioma 1Esophageal Neoplasms 1Endometrial Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Ovarian Epithelial 1Carcinoma, Hepatocellular 1Carcinoma, Endometrioid 1Carcinoma 1

Interventions

Paclitaxel 24Carboplatin 21Taxes 15Bevacizumab 9Cisplatin 7Immunoglobulin G 6Disulfides 6Topotecan 3Docetaxel 3paclitaxel poliglumex 2VTX-2337 2SS1(dsFv)PE38 2Platinum 2Peripheral Blood Stem Cell Transplantation 2Gemcitabine 2Filgrastim 2Etoposide 2Erlotinib Hydrochloride 2Chemotherapy, Adjuvant 21,2-diaminocyclohexaneplatinum II citrate 2veliparib 1trioctyl phosphine oxide 1sargramostim 1pegfilgrastim 1liposomal doxorubicin 1emactuzumab 1elesclomol 1dexamethasone acetate 1dexamethasone 21-phosphate 1belinostat 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Brenner Tumor × adavosertib × Gynecologic × Clear all
NCT02101775 2026-04-13

Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
124 enrolled 17 charts
Gynecologic

Brenner Tumor, Fallopian Tube Neoplasms, Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡